Evidence map›Paper›PMID 33648559›Full record

ArticleGenome medicine2021

Congruent microbiome signatures in fibrosis-prone autoimmune diseases: IgG4-related disease and systemic sclerosis.

Damian R Plichta, Juhi Somani, Matthieu Pichaud, Zachary S Wallace, Ana D Fernandes, Cory A Perugino, Harri Lähdesmäki, John H Stone, Hera Vlamakis, Daniel C Chung and 3 more

Open access · goldAbstract read
In one paragraph

Article in Genome medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Recent advances in the positive role ofFrontiers in immunology · 2026
    Review
  7. Virulence · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Omics in IgG4-related disease.Chinese medical journal · 2025
    Review
  13. Article
  14. Review
  15. Causal relationship between gut microbiota and diabetes based on Mendelian randomization.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Article
  16. Observational
  17. Article
  18. Article
  19. Immune network · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 2 countries.

Damian R PlichtaBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Juhi SomaniDepartment of Computer Science, Aalto University, 02150, Espoo, Finland.
Matthieu PichaudNovartis Institute for Biomedical Research, Cambridge, MA, USA.
Zachary S WallaceDivision of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA.
Ana D FernandesDivision of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA.
Cory A PeruginoDivision of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA.
Harri LähdesmäkiDepartment of Computer Science, Aalto University, 02150, Espoo, Finland.
John H StoneDivision of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA.
Hera VlamakisBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Daniel C ChungDivision of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Dinesh KhannaUniversity of Michigan Scleroderma Program, Ann Arbor, MI, USA.
Shiv PillaiRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Ramnik J XavierBroad Institute of MIT and Harvard, Cambridge, MA, USA. xavier@molbio.mgh.harvard.edu.ORCID 0000-0002-5630-5167
Broad Institute · USMassachusetts General Hospital · USAalto University · FIRagon Institute of MGH, MIT and Harvard · USHarvard University · USNovartis (United States) · USUniversity of Michigan · US

Funding

Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Mark Joseph Daly · 1991 to 2026
$35.3M
The importance of the IgG4 glycome in IgG4-related disease(s)U19AI110495 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI SHIV Subramaniam PILLAI · 2014 to 2026
$7.9M
Outcomes Research in Rheumatic DiseasesK24AR063120 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KHANNA, DINESH · 2012 to 2022
$1.6M
Targeting T cell Subsets in Autoimmune DiseaseUM1AI144295 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI John H Stone · 2019 to 2026
$1.4M
University of Michigan Autoimmunity Center of Excellence, Clinical Research ProgrUM1AI110557 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FOX, DAVID ALAN · 2014 to 2018
$543k
NIAID NIH HHS U19 AI110495NIAID NIH HHS UM1 AI110557NIAID NIH HHS UM1 AI144295NIAMS NIH HHS K24 AR063120NIDDK NIH HHS P30 DK043351NIH HHS K24 AR063120NIH HHS UM1 AI144295
6 · The paper itself

Abstract

backgroundImmunoglobulin G4-related disease (IgG4-RD) and systemic sclerosis (SSc) are rare autoimmune diseases characterized by the presence of CD4+ cytotoxic T cells in the blood as well as inflammation and fibrosis in various organs, but they have no established etiologies. Similar to other autoimmune diseases, the gut microbiome might encode disease-triggering or disease-sustaining factors.

methodsThe gut microbiomes from IgG4-RD and SSc patients as well as healthy individuals with no recent antibiotic treatment were studied by metagenomic sequencing of stool DNA. De novo assembly-based taxonomic and functional characterization, followed by association and accessory gene set enrichment analysis, were applied to describe microbiome changes associated with both diseases.

resultsMicrobiomes of IgG4-RD and SSc patients distinctly separated from those of healthy controls: numerous opportunistic pathogenic Clostridium and typically oral Streptococcus species were significantly overabundant, while Alistipes, Bacteroides, and butyrate-producing species were depleted in the two diseases compared to healthy controls. Accessory gene content analysis in these species revealed an enrichment of Th17-activating Eggerthella lenta strains in IgG4-RD and SSc and a preferential colonization of a homocysteine-producing strain of Clostridium bolteae in SSc. Overabundance of the classical mevalonate pathway, hydroxyproline dehydratase, and fibronectin-binding protein in disease microbiomes reflects potential functional differences in host immune recognition and extracellular matrix utilization associated with fibrosis. Strikingly, the majority of species that were differentially abundant in IgG4-RD and SSc compared to controls showed the same directionality in both diseases. Compared with multiple sclerosis and rheumatoid arthritis, the gut microbiomes of IgG4-RD and SSc showed similar signatures; in contrast, the most differentially abundant taxa were not the facultative anaerobes consistently identified in inflammatory bowel diseases, suggesting the microbial signatures of IgG4-RD and SSc do not result from mucosal inflammation and decreased anaerobism.

conclusionsThese results provide an initial characterization of gut microbiome ecology in fibrosis-prone IgG4-RD and SSc and reveal microbial functions that offer insights into the pathophysiology of these rare diseases.

Indexed as

Gastrointestinal MicrobiomeBacillotaBacteroidetesCase-Control StudiesCohort StudiesExtracellular MatrixFibrosisHumansImmunoglobulin G4-Related DiseaseScleroderma, SystemicSignal TransductionSpecies SpecificityAutoimmunityGut microbiomeIgG4-RDSystemic sclerosis

Identifiers

PMID33648559
PMCPMC7919092
OpenAlexW3134194768

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.